-transparent.png){kind=logo}
Twenty-three patients with Stage III, Stage IV, or recurrent epithelial ovarian cancer were treated with a combination of melphalan and levamisole to determine a tolerable dosage schedule, possible adverse effects, and a general estimate of response rate and duration. In seven patients with measurable disease there were four complete responses (57%) with a median duration of 75 weeks. Two of the complete responders have had negative second-look laparotomies while the other two patients have had subsequent progression. Of 16 patients with nonmeasurable disease two have had negative second-look laparotomies and two remain progression free. Thus 8 of 23 patients (35%) had complete responses or remain progression free whereas 4 of 23 patients (17%) have had negative second-look laparotomies. No serious toxicity was encountered. Immunologic monitoring did not indicate significant immunologic reconstitution in these immunosuppressed patients.
J P Gusdon, and
H D Homesley, and
H B Muss, and
E R Heise, and
G A Herbst, and
F Richards, and
C L Spurr, and
J V Lovelace, and
P J Di Saia
January 1986,
Investigational new drugs,
J P Gusdon, and
H D Homesley, and
H B Muss, and
E R Heise, and
G A Herbst, and
F Richards, and
C L Spurr, and
J V Lovelace, and
P J Di Saia
April 1992,
American journal of clinical oncology,
J P Gusdon, and
H D Homesley, and
H B Muss, and
E R Heise, and
G A Herbst, and
F Richards, and
C L Spurr, and
J V Lovelace, and
P J Di Saia
September 1986,
Gynecologic oncology,
J P Gusdon, and
H D Homesley, and
H B Muss, and
E R Heise, and
G A Herbst, and
F Richards, and
C L Spurr, and
J V Lovelace, and
P J Di Saia
March 1978,
Obstetrics and gynecology,
J P Gusdon, and
H D Homesley, and
H B Muss, and
E R Heise, and
G A Herbst, and
F Richards, and
C L Spurr, and
J V Lovelace, and
P J Di Saia
November 1990,
Investigational new drugs,
J P Gusdon, and
H D Homesley, and
H B Muss, and
E R Heise, and
G A Herbst, and
F Richards, and
C L Spurr, and
J V Lovelace, and
P J Di Saia
June 1985,
American journal of obstetrics and gynecology,
J P Gusdon, and
H D Homesley, and
H B Muss, and
E R Heise, and
G A Herbst, and
F Richards, and
C L Spurr, and
J V Lovelace, and
P J Di Saia
June 2019,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
J P Gusdon, and
H D Homesley, and
H B Muss, and
E R Heise, and
G A Herbst, and
F Richards, and
C L Spurr, and
J V Lovelace, and
P J Di Saia
June 2014,
Gynecologic oncology,
J P Gusdon, and
H D Homesley, and
H B Muss, and
E R Heise, and
G A Herbst, and
F Richards, and
C L Spurr, and
J V Lovelace, and
P J Di Saia
July 2013,
Gynecologic oncology,
J P Gusdon, and
H D Homesley, and
H B Muss, and
E R Heise, and
G A Herbst, and
F Richards, and
C L Spurr, and
J V Lovelace, and
P J Di Saia
September 1982,
Cancer treatment reports,
